Oncology Research and Treatment

Published by: S. Karger AG  

People

  1. O'Reilly
    O'Reilly
  2. Panageas
    Panageas
  3. Scheinberg
    Scheinberg

Groups

  1. Center for Hematologic Malignancies (4)
  2. Department of Medicine (4)
  3. GSK Faculty (4)
  4. Hematologic Malignancies, Division of (4)
  5. Immunology Program Faculty (4)
  6. Sloan Kettering Institute Faculty (4)
  7. Executive Committee, Center for Hematologic Malignancies (3)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  9. Adult Leukemia (1)
  10. Biostatistics Service (1)
Search Within
  1. "Immunology Program Faculty"
Formats
  1. Meeting Abstract (4)
Groups
  1. Center for Hematologic Malignancies (4)
  2. Department of Medicine (4)
  3. GSK Faculty (4)
  4. Hematologic Malignancies, Division of (4)
  5. Immunology Program Faculty (4)
  6. Sloan Kettering Institute Faculty (4)

More Groups

People
  1. Marcel Van Den Brink (3)
  2. David Scheinberg (1)
  3. Katherine Panageas (1)
  4. Matthew Hellmann (1)
  5. Richard O'Reilly (1)
  6. Timothy Chan (1)

More People

Years
  1. 2023 (1)
  2. 2019 (1)
  3. 2017 (1)
  4. 2016 (1)
Publishers
  1. S. Karger AG (4)

Results (4)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Tumor cell-intrinsic activity of the RNA receptor RIG-I promotes checkpoint inhibitor-mediated anticancer immunity
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Stritzke, F.; Bek, S.; Steiger, K.; Winter, C.; Rad, R.; van den Brink, M. R. M.; Ruland, J.; Bassermann, F.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Anti-CTLA-4 checkpoint inhibitormediated anticancer immunity relies on tumor-intrinsic RIG-I signaling
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Bek, S.; Schmickl, M.; Steiger, K.; Koenig, P. A.; Ruland, J.; van den Brink, M. R. M.; Peschel, C.; Haas, T.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • Activation of the cytosolic RNA receptor RIG-I in tumor and immune cells triggers efficient anti-tumor immunity and synergizes with checkpoint blockade
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Kreppel, D.; Bscheider, M.; Bek, S.; Fischer, J.; Schmickl, M.; Ruland, J.; van den Brink, M.; Peschel, C.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save

    • Oncology Research and Treatment – authorized name for:

    Name ISSN / ISBN Publisher
    Oncology Research and Treatment 22965270 Unknown
    Oncology Research and Treatment 2296-5270 Karger
    Oncology research and treatment 22965262 Unknown
    Oncology Research and Treatment 2296-5270 S. Karger AG
    Oncology Research and Treatment 2296-5270 S. Karger AG